"All of the patients in the treatment group had EHS ≤ 2 at visit 1. At FU1 (1 month post-final treatment) 90% of the treated patients (54/60) reported functional erections defined as EHS ≥ 3 and were able to achieve vaginal penetration. At FU1, 100% of the patients in the treatment group had an improvement in their EHS by at least one grade."
"The number of studies of LI-ESWT for ED have increased dramatically in recent years. Most of these studies presented encouraging results, regardless of variation in LI-ESWT setup parameters or treatment protocols. These studies suggest that LI-ESWT could significantly improve the IIEF and EHS of ED patients... We reviewed 14 studies of men who received low-intensity extracorporeal shock wave treatment (LI-ESWT) for erectile dysfunction (ED). There was evidence that these men experienced improvements in their ED following LI-ESWT."
"The majority of patients have PD history longer than 6 months (mean, 12.8 months; range, 6–28 months). Two thirds of patients have received and failed oral medical therapy. There were improvements in penile curvature (more than 15 degrees in 33% of men), plaque hardness (60% of men) and penile pain (4 out of 6 men) following LiESWT. There was a moderate improvement in IIEF-5 score (>5 points reported in 20% of men). No complication was reported and the majority of patients were satisfied (rated 4 out of 5; 70% of men) and would recommend this therapy to others."
"The application of extracorporeal shockwave therapy (ESWT) in musculoskeletal disorders has been around for more than a decade and is primarily used in the treatment of sports related over-use tendinopathies such as proximal plantar fasciitis of the heel, lateral epicondylitis of the elbow, calcific or non-calcific tendonitis of the shoulder and patellar tendinopathy etc. The success rate ranged from 65% to 91%, and the complications were low and negligible. ESWT is also utilized in the treatment of non-union of long bone fracture, avascular necrosis of femoral head, chronic diabetic and non-diabetic ulcers and ischemic heart disease. The vast majority of the published papers showed positive and beneficial effects."
"ESWT has been proven as effective and safe noninvasive treatment option for tendon and other pathologies of the musculoskeletal system in a multitude of high-quality RCTs. For plantar fasciopathy, noncalcific tendinopathy of the supraspinatus tendon and calcifying tendonitis of the shoulder RCTs on ESWT are the predominant type of RCT in PEDro and obtained the highest PEDro scores among all investigated treatment modalities for these conditions. The latter criterion was also achieved for Achilles tendinopathy and lateral epicondylitis, albeit in a smaller number of RCTs. Therefore, ESWT should be considered by medical doctors, therapists, patients and payers when discussing treatment options for certain musculoskeletal pathologies."
"Before ESWT, the plantar fasciitis side was ultrasonographically significantly thicker than the control side (p<0.05), whereas 6 months after ESWT, the thickness of the fascia was no longer significantly different. The decrease in thickness of the plantar fasciitis side was significant (p<0.05). Pain during activities of daily living decreased by 79% according to the VAS, and the comfortable walking time increased, both significantly (p<0.01). In patients with little pain (VAS<30), the thickness of the plantar fasciitis side was significantly less (p<0.01) compared with patients who still suffered more pain (VAS>30)."
"88% of the verum group achieved freedom from pain or good results. In the placebo group, no pain relief was achieved, 33.3% showed good results (score n. Roles and Maudsley). The verum group showed significantly better results in morning, rest pain, puncture tolerance and walking ability. The pedograph showed no clear correlation between pain improvement and stress behavior."
"The ESWT group received 3,000 impulses (energy flux density, 0.08 mJ/mm2), while the sham ESWT group received 30 impulses (energy flux density, 0.08 mJ/mm2). Pain was significantly lower in the ESWT group than the sham ESWT group, which persisted up to 24 months post-treatment. In the present study, pain decreased to a significantly greater extent in the ESWT group than in the US group. Furthermore, the therapeutic effect persisted for 3 months post-treatment, indicating the effectiveness of the ESWT treatment protocol."